Sector News

Roche chairman sees opportunities for drugmakers under Trump

January 29, 2018
Life sciences

Fears U.S. President Donald Trump could damage the drugs industry have not been realized and the administration’s efforts to accelerate new medicine approvals will bolster the sector, the chairman of Swiss drugmaker Roche said.

“The U.S. Food and Drug Administration (FDA) wants to trim the time it takes for drugs to be approved,” Christoph Franz told Swiss newspaper Blick in an interview published on Friday.

“European regulators, when it comes to approving new medicines, are lagging the Americans by around six to 12 months. Europe has some catching up to do.”

FDA Commissioner Scott Gottlieb, whom Trump brought in, aims to approve drugs based on very early data if they show a possible survival benefit, among other measures to get medicines on the market faster.

After he was elected, Trump blasted drug companies, saying they had been “getting away with murder” with high prices.

While the Trump administration has since sought to change how hospitals are reimbursed for some drugs, his selection of Gottlieb, with deep ties to the drug industry, eased worries that he would seek a confrontation.

“Fears that Trump would damage the pharmaceuticals branch have not been realized,” Franz, who was in Davos for the World Economic Forum meeting, told Blick in the interview.

“It’s quite the opposite. We see new opportunities.”

By John Miller

Source: Reuters

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend